Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM).

被引：6
|
作者：
Lokhorst, Henk M.
Laubach, Jacob
Nahi, Hareth
Plesner, Torben
Gimsing, Peter
Hansson, Markus
Minnema, Monique
Lassen, Ulrik Niels
Krejcik, Jakub
Ahmadi, Tahamtan
Lisby, Steen
Basse, Linda
Brun, Nikolai C.
Richardson, Paul G.
机构：
[1] UMC Utrecht, Utrecht, Netherlands
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Karolinska Univ Sjukhuset Huddinge, Huddinge, Sweden
[4] Vejle Hosp, Vejle, Denmark
[5] Copenhagen Univ Hosp, Copenhagen, Denmark
[6] Skane Univ Hosp, Lund, Sweden
[7] Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark
[8] Janssen Res & Dev, Spring House, PA USA
[9] Genmab AS, Copenhagen, Denmark
[10] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.8513
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8513
引用
收藏
页数：1
相关论文
共 50 条
  • [1] DOSE-DEPENDENT EFFICACY OF DARATUMUMAB (DARA) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RR MM)
    Lokhorst, H.
    Laubach, J.
    Nahi, H.
    Plesner, T.
    Gimsing, P.
    Hansson, M.
    Minnema, M.
    Lassen, U.
    Krejcik, J.
    Ahmadi, T.
    Khan, I.
    Uhlar, C.
    Lisby, S.
    Basse, L.
    Brun, N.
    Richardson, P.
    HAEMATOLOGICA, 2014, 99 : 106 - 107
  • [2] Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
    Usmani, Saad
    Weiss, Brendan
    Bahlis, Nizar J.
    Belch, Andrew
    Lonial, Sagar
    Lokhorst, Henk
    Voorhees, Peter M.
    Richardson, Paul G.
    Sasser, A. Kate
    Axel, Amy
    Feng, Huaibao
    Uhlar, Clarissa
    Wang, Jianping
    Khan, Imran
    Ahmadi, Tahamtan
    Nahi, Hareth
    BLOOD, 2015, 126 (23)
  • [3] Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
    Usmani, Saad Z.
    Weiss, Brendan M.
    Plesner, Torben
    Bahlis, Nizar J.
    Belch, Andrew
    Lonial, Sagar
    Lokhorst, Henk M.
    Voorhees, Peter M.
    Richardson, Paul G.
    Chari, Ajai
    Sasser, A. Kate
    Axel, Amy
    Feng, Huaibao
    Uhlar, Clarissa M.
    Wang, Jianping
    Khan, Imran
    Ahmadi, Tahamtan
    Nahi, Hareth
    BLOOD, 2016, 128 (01) : 37 - 44
  • [4] Pomalidomide, Cyclophosphamide and Dexamethasone (PCD) is an effective salvage regimen for multiple myeloma (MM) patients relapsed and/or refractory to Daratumumab (dara)
    Brioli, A.
    Ernst, T.
    Hilgendorf, I.
    Heidel, F.
    Hunstig, F.
    Stauch, T.
    Hochhaus, A.
    von Lilienfeld-Toal, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 278 - 278
  • [5] Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).
    Gasparetto, Cristina
    Lentzsch, Suzanne
    Schiller, Gary J.
    Callander, Natalie Scott
    Tuchman, Sascha
    Bahlis, Nizar J.
    White, Darrell
    Chen, Christine
    Baljevic, Muhamed
    Sutherland, Heather J.
    Kotb, Rami
    Sebag, Michael
    LeBlanc, Richard
    Venner, Christopher P.
    Bensinger, William
    Rossi, Adriana C.
    Sheehan, Heidi
    Arazy, Melina
    Kai, Kazuharu
    Lipe, Brea
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Daratumumab monotherapy in heavily pretreated Asians patients with relapsed and refractory multiple myeloma
    Yoon, Sung-Soo
    Byun, Ja Min
    Park, Hyunkyung
    Lee, Ji Yun
    Koh, Youngil
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E155 - E156
  • [7] Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma
    Salomon-Perzynski, Aleksander
    Walter-Croneck, Adam
    Usnarska-Zubkiewicz, Lidia
    Dytfeld, Dominik
    Zielinska, Patrycja
    Wojciechowska, Malgorzata
    Holojda, Jadwiga
    Robak, Pawel
    Pasternak, Anna
    Knopinska-Posluszny, Wanda
    Hawrylecka, Dorota
    Wojtowicz, Marcin
    Szeremet, Agnieszka
    Osowiecki, Michal
    Mordak-Domagala, Monika
    Zaucha, Jan Maciej
    Giannopoulos, Krzysztof
    Warzocha, Krzysztof
    Jamroziak, Krzysztof
    ADVANCES IN MEDICAL SCIENCES, 2019, 64 (02): : 349 - 355
  • [8] Durvalumab (DURVA) plus daratumumab (DARA) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).
    Richardson, Paul G.
    Bensinger, William
    Weisel, Katja C.
    Boyd, Kevin
    Ramasamy, Karthik
    Gonzalez, Esther
    Favre-Kontula, Linda
    Peluso, Teresa
    Sternas, Lars Axel
    Di Casoli, Carl
    Zaki, Mohamed H.
    Facon, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma
    贾亚静
    China Medical Abstracts(Internal Medicine), 2020, 37 (03) : 189 - 189
  • [10] Dose-dependent effect of thalidomide (Thal) on overall survival (OS) in relapsed and refractory multiple myeloma (MM).
    Neben, K
    Moehler, TM
    Benner, A
    Kraemer, A
    Ho, AD
    Goldschmidt, H
    BLOOD, 2001, 98 (11) : 163A - 163A
12345